Movement Disorders

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending May 19, 2023.

Treatment with valbenazine at doses of up to 80 mg once per day significantly improved chorea, as demonstrated by the mean change in UHDRS Total Maximal Chorea scores.

Neurological rehabilitation, or neurorehabilitation, can be described as the use of rehabilitation interventions to improve or maintain function and quality of life in the context of neurological conditions.

Marcelo Bigal, MD, PhD, chief executive officer of Ventus Therapeutics, talked about the relationship between inflammation and neurodegeneration in Parkinson disease, and the importance of targeting NLRP3.

Differences in personal experience of dyskinesias in Parkinson disease were observed across multiple cultures, which could be attributable to intrinsic cultural peculiarities.

Timothy A. Leichliter, MD, a neurologist at Allegheny Health Network, provided context on the institution’s boxing program for Parkinson disease, and the need for patients to remain active.

Participants with rheumatoid arthritis had a 1.74-fold higher risk of PD compared with those without, raising importance of an elevated risk.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is headache and migraine.

Jean-Cosme Dodart, PhD, senior vice president of research at Vaxxinity, discussed the progress of the UB-312 Parkinson disease vaccine, highlighting its findings from a phase 1 clinical trial, and plans for a phase 2 trial.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending May 12, 2023.

Taken together, the findings added to the growing evidence that widespread immunological and autonomic nervous system changes may contribute to long COVID.

The CEO and cofounder of Amprion spoke about additional diagnostic uses of the αSyn seed amplification assay and its validation in the Parkinson's Progression Markers Initiative study at the 2023 AAN Annual Meeting. [WATCH TIME: 6 minutes]

The expert panel reviews unmet needs in treatment and management of dyskinesia and shares advice for physicians treating patients with Parkinson disease.

Drs Fernando Pagan, Robert A. Hauser, and Daniel Kremens highlight existing and emerging surgical and pharmacological options for treatment of dyskinesia in Parkinson disease.

Poor higher order vision at baseline was associated with worsening cognition and increased probability of death, dementia, or frailty over 3 years.

Stuart H. Isaacson, MD, FAAN, offers insight into the challenges faced when attempting to achieve long-term symptom control for patients with Parkinson disease.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is epilepsy and seizure disorders.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending May 5, 2023.

Designed for self-directed use in a patient’s home or a healthcare facility, the Cumulus EEG device has potential to change the clinical trial landscape, allowing researchers to conduct more remote studies.

Over 48 weeks of treatment, ALXN1480 was found to be generally well-tolerated, with improvements seen in Clinical Global Impression-Improvement scores and UWDRS Parts II and III.

A group of experts in the care of patients with neurological conditions—Ali Jannati, MD, PhD; Madhav R. Thambisetty, MD, PhD; Daniel Ontaneda, MD, PhD; Peter J. Goadsby, MD, PhD, DSc; Andrew Russman, DO—shared their perspectives on hot topics of treatment and management in neurology from the 2023 American Academy of Neurology Annual Meeting.

The director of Cleveland Clinic’s Epilepsy Center at the Cleveland Clinic Neurological Institute provided perspective on the in-depth testing neurologically healthy patients in the Brain Study will undergo. [WATCH TIME: 3 minutes]

The expert neurology panel shares their clinical experience with different formulations of amantadine in management of dyskinesia in patients with Parkinson disease.

The expert panel reviews the safety profile of amantadine DR/ER and who may be an ideal patient for its use in patients with Parkinson disease experiencing dyskinesia.

An expert in the management of Parkinson disease discusses the key role that shared decision-making plays in the modern treatment paradigm.

Here's some of what is coming soon to NeurologyLive® this week.

Neurology News Network for the week ending April 30, 2023. [WATCH TIME: 4 minutes]

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is the history of the American Academy of Neurology.